Tango Therapeutics Stock Today
| TNGX Stock | USD 3.10 0.16 5.44% |
Performance0 of 100
| Odds Of DistressLess than 33
|
Tango Therapeutics is trading at 3.10 as of the 21st of December 2024; that is 5.44 percent increase since the beginning of the trading day. The stock's open price was 2.94. Tango Therapeutics has about a 33 percent probability of financial distress in the next few years of operation and has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 21st of November 2024 and ending today, the 21st of December 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 3rd of September 2020 | Category Healthcare | Classification Health Care |
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. The company was founded in 2017 and is based in Cambridge, Massachusetts. Tango Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 107.42 M outstanding shares of which 7.22 M shares are at this time shorted by private and institutional investors with about 2.31 trading days to cover. More on Tango Therapeutics
Moving together with Tango Stock
Moving against Tango Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Tango Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO President | Barbara MD | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsTango Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Tango Therapeutics' financial leverage. It provides some insight into what part of Tango Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Tango Therapeutics (TNGX) is traded on NASDAQ Exchange in USA. It is located in 201 Brookline Avenue, Boston, MA, United States, 02215 and employs 140 people. Tango Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 315.81 M. Tango Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 107.42 M outstanding shares of which 7.22 M shares are at this time shorted by private and institutional investors with about 2.31 trading days to cover.
Tango Therapeutics currently holds about 416.36 M in cash with (117.98 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.73, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Tango Therapeutics Probability Of Bankruptcy
Ownership AllocationThe majority of Tango Therapeutics outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Tango Therapeutics to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Tango Therapeutics. Please pay attention to any change in the institutional holdings of Tango Therapeutics as this could imply that something significant has changed or is about to change at the company.
Check Tango Ownership Details
Tango Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Balyasny Asset Management Llc | 2024-09-30 | 2.7 M | |
| State Street Corp | 2024-09-30 | 2.3 M | |
| Adage Capital Partners Gp Llc | 2024-09-30 | 2.3 M | |
| Deerfield Management Co | 2024-09-30 | 1.5 M | |
| Geode Capital Management, Llc | 2024-09-30 | 1.4 M | |
| Casdin Capital, Llc | 2024-09-30 | 1.2 M | |
| Baker Bros Advisors Lp | 2024-09-30 | 750 K | |
| Arrowmark Colorado Holdings, Llc (arrowmark Partners) | 2024-09-30 | 708.4 K | |
| Bessemer Group Inc | 2024-09-30 | 708.4 K | |
| Trv Gp Iv, Llc | 2024-09-30 | 16.9 M | |
| Ecor1 Capital, Llc | 2024-09-30 | 13.3 M |
Tango Therapeutics Historical Income Statement
Tango Stock Against Markets
Tango Therapeutics Corporate Management
| MD Kaelin | Founder Board | Profile | |
| Antoni MD | Founder Board | Profile | |
| Daniella CPA | Chief Officer | Profile | |
| Alan Huang | Chief Officer | Profile | |
| Levi MD | Founder | Profile | |
| JD Esq | Chief Counsel | Profile |
Additional Tools for Tango Stock Analysis
When running Tango Therapeutics' price analysis, check to measure Tango Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tango Therapeutics is operating at the current time. Most of Tango Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tango Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tango Therapeutics' price. Additionally, you may evaluate how the addition of Tango Therapeutics to your portfolios can decrease your overall portfolio volatility.